Company / Free Cash Flow
Vera Therapeutics, Inc. Free Cash Flow History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$241.7M
FY2025
5-year range
-$241.7M / -$23.7M
FY2021-FY2025
Trend
-78.2%
vs FY2024
Sector context
#159 of 194
Health Care
What the data says
Vera Therapeutics, Inc.'s free cash flow of -$242M is lower than 82% of companies in the Health Care sector (FY2025). Free Cash Flow has declined for 4 consecutive years, from -$24M in FY2021 to -$242M in FY2025.
Based on SEC 10-K filings.
-$242M in FY2025.
Declined from -$92M to -$242M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 194This company -$241.7M Sector average $470.6M
▼
-151.4% below sector average
Key checks
Key Insights
- Vera Therapeutics, Inc.'s free cash flow has declined for 4 consecutive years.
- In FY2025, free cash flow decreased 78.2% year-over-year.
- Ranks #159 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$241.7M | -78.2% |
| FY2024 | -$135.7M | -47.1% |
| FY2023 | -$92.2M | -36.3% |
| FY2022 | -$67.7M | -185.4% |
| FY2021 | -$23.7M | +32.1% |
| FY2020 | -$34.9M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026